Glasgow, Scotland. With the aim of improving clinical outcome in cancer patients, TC BioPharm (TCB) and Sistemic will work together to develop a range of biomarkers designed to provide valuable information on individual patient responses to TCB’s innovative cell therapy product.
Glasgow, Scotland Sistemic Ltd announced today that the company had been short-listed as one of the top 10 companies to watch in the developing stem cell sector by the well regarded digest StemCellAssays.
Sistemic will be attending the 4th Cell Therapy Conference: Manufacturing and Testing of Pluripotent Stem Cells in June to highlight the development of SistemPSCCheck™ - the world’s first commercial assay for assessment of pluripotent stem cell contamination in derived cell therapy products
GLASGOW, SCOTLAND Sistemic will be attending Phacilitate Cell & Gene Therapy World and the World Stem Cell Summit in January to highlight the development of their assay for assessment of pluripotent stem cell contamination in derived cell therapy products
Glasgow, SCOTLAND. Sistemic Ltd. is excited to announce significant progress with the development of a miRNA-based assay for assessment of pluripotent stem cell (PSC) contamination in derived cell therapy products. The development is being undertaken in conjunction with LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement.
Glasgow, Scotland Sistemic Ltd announced today the award of an Innovate UK grant to further develop, to a market-ready stage, its groundbreaking prototype microRNA-based assay for accurate assessment of pluripotent stem cell contamination in derived cell therapy products.